Sinovac Biotech successfully listed on the Shanghai Stock Exchange’s STAR Market in December 2020 through its IPO. However, financial disclosures before and after the listing revealed a persistent rise in accounts receivable, drawing market attention. According to its prospectus, the company’s accounts receivable increased from approximately RMB 230 million in 2017 to nearly RMB 500 million in 2019, with the ratio to revenue climbing year over year. This trend suggests that while expanding sales, Sinovac faces mounting pressure on cash collection—potentially due to high customer concentration, lenient credit policies, or long industry-wide payment cycles.Elevated accounts receivable not only tie up working capital but also increase the risk of bad debts, potentially undermining cash flow and profitability. Although Sinovac claims it has strengthened receivables management and implemented credit assessments for major clients, investors should remain cautious about these underlying financial risks. Particularly in China’s biopharmaceutical sector—where centralized drug procurement drives down prices and extends payment terms—inefficient collections could constrain Sinovac’s long-term growth.In summary, while the IPO provided Sinovac with valuable capital, its rising accounts receivable remains a critical indicator of operational quality and risk management that warrants close scrutiny.
科兴制药于2020年12月成功登陆科创板，完成IPO。然而，其上市前后披露的财务数据显示，公司应收账款持续走高，引发市场关注。招股书显示，2017年至2019年，科兴制药的应收账款从约2.3亿元增长至近5亿元，占营业收入比重逐年上升。这一趋势反映出公司在扩大销售规模的同时，回款能力面临压力，可能存在客户集中度高、信用政策宽松或行业回款周期较长等问题。高企的应收账款不仅占用企业营运资金，还可能带来坏账风险，影响公司现金流和盈利能力。尽管科兴制药表示已加强应收账款管理，并对主要客户进行信用评估，但投资者仍需警惕其潜在的财务风险。尤其是在生物医药行业普遍面临集采压价、回款周期延长的背景下，科兴制药若不能有效改善回款效率，或将对其长期发展构成制约。总体来看，科兴制药IPO虽为其带来资本助力，但应收账款问题不容忽视，是衡量其经营质量与风险控制能力的重要指标。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/3739.html